Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are the standard of care for metastatic renal cell carcinoma (RCC); however, most patients develop de novo or acquired resistance to ICIs. Oxidative phosphorylation (OXPHOS) has...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have